Graduate Theses, Dissertations, and Problem Reports
2003

Cytogenetic analysis of primary breast tumors and MCF10A cells
to determine early steps of breast carcinoma
Mohammad Mah Odetallah
West Virginia University

Follow this and additional works at: https://researchrepository.wvu.edu/etd

Recommended Citation
Odetallah, Mohammad Mah, "Cytogenetic analysis of primary breast tumors and MCF10A cells to
determine early steps of breast carcinoma" (2003). Graduate Theses, Dissertations, and Problem Reports.
1741.
https://researchrepository.wvu.edu/etd/1741

This Thesis is protected by copyright and/or related rights. It has been brought to you by the The Research
Repository @ WVU with permission from the rights-holder(s). You are free to use this Thesis in any way that is
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license
in the record and/ or on the work itself. This Thesis has been accepted for inclusion in WVU Graduate Theses,
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU.
For more information, please contact researchrepository@mail.wvu.edu.

Cytogenetic Analysis of Primary Breast Tumors and MCF10A Cells to
Determine Early Steps of Breast Carcinoma

Mohammad Odetallah
B.Sc., Bethlehem University, 2000

Thesis submitted to
Davis College of Agriculture, Forestry and Consumer Sciences
At West Virginia University
in partial fulfillment of the requirements
for the degree of
Master of Science in Genetics and Developmental Biology

Sharon Wenger, Ph.D., Chair
Jeannine Strobl, Ph.D.
Linda Sargent, Ph.D.

Department of Genetics and Developmental Biology

Morgantown, West Virginia
2003

Keywords: Breast Cancer, DCIS, MCF10A, Early Events, SKY, FISH, Cytogenetics,
Conventional Karyotyping.
Copyright 2003 Mohammad Odetallah

Abstract
Cytogenetic Analysis of Primary Breast Tumors and MCF10A Cells to
Determine Early Steps of Breast Carcinoma

Mohammad Odetallah
Breast cancers are characterized by genomic instability, abnormal chromosomal
counts and multiple translocations. There is a heavy burden on tumor cells to acquire as
many mutations as possible in a short time. Tumors seem to achieve that through
genomic instability. The role of homologous recombinational repair loss has been well
established as a mechanism of chromosomal instability. A researcher at the University of
Pittsburgh, Dr. Jean Latimer, was able to demonstrate the loss of nucleotide excision
repair (NER), in adjacent non tumor tissue. NER functions in bulky adducts repair,
following UV radiation. These lesions introduce a bend in the DNA molecule blocking
replication and transcription; therefore causing genomic instability. Some of the 30
polypeptides of NER were shown to be lost during different stages of breast cancer
development. The aim of the study was to cytogenetically analyze primary breast tumors
and MCF10A cells and to check for chromosomal abnormalities in these cultures with a
special focus on early events.
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I. INTRODUCTION
1-Breast Cancer:
The American Cancer Society estimates that 1,334,100 cancer cases will be
diagnosed in the USA alone for the year 2003. Of these cases, 212,600 will be breast
cancer. About 40,200 of these cases will die. All in all, more than 100 women will die of
breast cancer everyday in the USA. In that sense, breast cancer is only second to lung
cancer as a cause of cancer deaths among women. The state of West Virginia will have
11300 cases of cancer, of which more than 14% will be female breast cancer (Facts and
Figures 2002, American Cancer Society). However, improvements in therapy and earlier
diagnosis during the 1990s helped reduce mortality rates of breast cancer.

The understanding of early changes leading to breast cancer is vital for
therapeutic strategies. These genetic changes leading to breast cancer can include the loss
of nucleotide excision repair mechanism.

2-Breast Cancer Stages:
Breast cancer is classified in different stages based on the size and location of the
tumor. Stage 0 is cancer that has not spread beyond the breast ductal system. Two types
of stage 0 are often diagnosed: ductal carcinoma in situ (DCIS) and lobular carcinoma in
situ (LCIS) based on which part of the milk duct is affected. However, both seem to arise
from earlier non-malignant lesions called terminal ductal lobular units (TDLU). DCIS is
also classified into high (comedo), intermediate, and low (non-comedo) based on the
nuclear diameter, chromatin integrity and nuclear necrosis (Harris et al., 2000). All in all,
the 5-year relative survival rate for stage 0 is 100%. However, stage 0, especially DCIS,
is a marker for higher cancer risk anywhere in the breast. The second stage is stage I. In
this stage the size of the tumor is 2 cm or less and it has not metastasized to other parts of
the breast. The 5-year relative survival rate is 98%. The next stage is stage II which is
subdivided into stage II A, and B. In stage IIA, the primary tumor is between 2 -5 cm and
1

has not metastasized. In stage IIB, the primary tumor shares one of the two features of A
but the tumor is either over 5 cm in size or it has metastasized to the axillary lymph nodes
(never both). The 5-year relative survival rate for stage IIA is 88%, while for stage IIB is
76%. The fourth stage is stage III A, and B. Stage IIIA is characterized by spreading to
both axillary lymph nodes and axillary tissues. In stage IIIB, however, the primary tumor
can be of any size, has attached itself to the chest wall and has invaded the chest lymph
nodes. Stages IIIA and B have a 5-year relative survival rate of 56% and 49%
respectively. The last stage is stage IV in which the primary cancer has invaded other
parts of the body. At this stage, the 5-year relative survival rate dramatically falls to 16%
(The Breast Health Specialists, Imaginis).

3-Familial and Sporadic Breast Cancer:
Generally, solid tumors differ from leukemias. The latter requires one major
genetic event for neoplastic transformation, while the former involves multiple genes
with complex interactions among normal and mutant genes that allow the cells to escape
cell cycle regulations, apoptosis and dependence on growth signals, resulting in limitless
cell proliferation, creation of new blood vessels and the ability to metastasize (Hemminki
et al., 2001). Breast cancer is not an exception from these limitations. A loss in at least
one of the DNA repair mechanisms might be a vital step for the purpose of acquiring all
these prerequisites. In inherited breast cancer, the first mutation is inherited. The second
mutation is acquired through loss of heterozygosity, epigenetic changes or gene mutation.
Most of the inherited cases (5% of all breast cancer cases) start with a mutation in
BRCA1 or BRCA2 which is a mutation in DNA repair. Other susceptibility genes with
lower penetrance for breast cancer exist; such as ATM (Ataxia telangactasia mutated
gene), Li-Fraumani (p53 gene), Cowden’s disease (PTEN gene), Bloom syndrome
(chromosome 15) and most recently CHK2 (suspected gene called male and female
breast cancer risk) (Brody, 2002). These inherited cases are generally bilateral or multiple
tumors with early age of onset. For instance, the pathology of BRCA1 cancers, in
contrast to BRCA2 and familial cases, is characterized as high grade, hormone receptor
negative, Her2 non-overexpressing infiltrating ductal adenocarcinomas (Moynahan,
2

2002). Most of them show normal expression of cyclinD1, p21, and p53. All in all, they
seem to be extremely heterogenous in their histologic patterns. Individuals with BRCA1
mutations have a relative higher risk for breast, ovarian and fallopian tube cancers. On
the other hand, sporadic and BRCA2 breast cancers have similar molecular profile with a
large proportion being hormone receptor positive. BRCA2 tumors are less heterogenous
than those of BRCA1 (Moynahan, 2002). Unlike BRCA1 mutations, BRCA2 mutations
increase risk not only for breast cancer (to a lower extent than BRCA1), but also for other
types of cancer, such as male breast, pancreas and prostate cancers (Moynahan, 2002).
Finally, it is important to emphasize not only the multi genetic nature of cancer, but also
the role of modifier genes and the role of environment. Cancers, including breast cancer,
are the outcome of the interaction of all these factors. For instance, age, obesity,
menstrual history, smoking, alcohol consumption, and oral contraceptive use, are risk
factors for breast cancer. That helps explain the variation within the same hereditary
cancer in terms of incomplete penetrance, age of onset and prognosis of the disease
(Ponder, 1990).

BRCA1 was mapped to 17q21 by Hall and colleagues in 1990 (Hall et al., 1990).
The gene was identified by Miki et al. in 1994. BRCA1 behaves as recessive gene at the
cellular level and as Mendelian dominant gene at the population level in familial breast
cancer with a penetrance of 85% (OMIM). The frequency of the mutant allele (loss of
function mutations) q is 0.0033 (OMIM). The lifetime risk of developing breast cancer
for BRCA1 carriers is 92% compared to a general population risk of 10% (OMIM).

BRCA1 functions in homologous recombinational repair (HRR) of double strand
breaks and of DNA crosslinks. It acts as part of a large complex called the BRCA1associated genome surveillance complex (BASC) which might act as a sensor for DNA
damage (Bernstein et al. 2002). BRCA1 has a Rad51 interaction domain. Together, they
participate in the repair of double stand breaks and DNA crosslinks. In addition to HRR,
BRCA1 plays a role in the cell cycle and apoptosis. For instance, it was shown to
transcriptionally induce the growth arrest and DNA damage inducible gene 45
(GADD45). That in turn activates the G2/M checkpoint and might activate JNK/SAPK
3

apoptotic pathway. BRCA1 also has an interaction domain for p53. Once phosphorylated,
BRCA1 is thought to act synergistically with p53 in the p53 pathway for cell cycle arrest
and DNA damage response. Later on, p53 down regulates the levels of BRCA1.
However, under excessive DNA damage, BRCA1 might activate apoptosis independent
of p53. This is achieved through the induction of Fas-dependent pathway which ends in
the activation of procaspase-8 (Bernstein et al. 2002). All in all, BRCA1 is essential for
genomic stability and mutations in both alleles allow the cell to rapidly acquire new
mutations (Moynahan, 2002). Recently, there is evidence that BRCA1 is down regulated
or even repressed in the majority of high grade sporadic ductal carcinomas (Shen et al.,
2000). However, most sporadic breast cancers seem to have normal expression for
BRCA1.

4-Nucleotide Excision Repair (NER):
DNA damage could occur as a result of a variety of exogenous and endogenous
factors, such as UV radiations, free radicals, etc. Such damage could block DNA
replication, transcription or could result in mutation, if not repaired. However, both
eukaryotic and prokaryotic organisms have developed mechanisms to repair DNA
damage. One of these mechanisms is NER. NER functions in repairing damage caused by
UV light in the form of bulky adducts, such as; cyclobutane pyrimidine dimers and
pyrimidine (6-4) pyrimidone photoproducts. These lesions are not only chemically
different; they also induce a bend in the DNA molecule (Ura et al., 2002). Consequently,
a deficit in NER has broad impact on genomic stability especially after UV exposure.
Classical examples of inherited NER deficiencies are xeroderma pigmentosum (XP),
cockayne syndrome (CS) and trichothiodystrophy (TTD-A). These individuals are highly
sensitive to UV light and individuals with XP are predisposed to skin cancer.
Interestingly, NER capability seems to be lost in breast tumors and in adjacent non tumor
tissue (Latimer et al., 2002).
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Table I. The NER Proteins.
NER

Chromos- Functional aspects and domains

genes

ome locus

XPA

9q22.3

Zinc finger, affinity for ssDNA damage

Role NER

Damage
recognition

XPB

2q21

3/ to 5/

Helicase, DNA dependent Assembly of

ATPase, acts with TFIIH
XPC

3p25.1

Ubiquitin, specific to GG-NER, DNA Stabilization of
binding

XPD

19q13.3

preincision complex

preincision complex

5/ to 3/ helicase, DNA dependent Transcription
ATPase, involved in Pol II basal repair coupling
transcription, acts with TFIIH

XPE:
- P127

11q12-13

- Damaged DNA binding protein

- P48

11p12-11

- Damage detection

XPF

16p13.13

Endonuclease

5/ incision

XPG

13q33

Endonuclease

3/ incision

ERCC1

19q13.2

Acts with XPF

May catalyze 5/
incision

LIG I

19q13.2

Ligase

DNA ligation

CS-B

10q11.2

Helicase? Part of RNA Pol II complex

hHR23A

19q13.2

Can substitute for hHR23B

hHR23B

9q31.2

May contribute to preincision complex Stimulate XPC
stability

RPA70

17p13.3

Cooperative binding to damaged DNA
with XPA

RPA32

1p35

Phosphorylated for regulation

RPA14

7p22

Stabilizes RPA complex

5

Helicase activity

TFIIH
- P34

12q24.31

- P52

6p21.3

- P44

5q12.2-

Zinc finger domain

and damage
recognition

Zinc finger domain

q13.3
TFIIEp56 3q21-24

Acts as part of TFIIE to inhibit TFIIH

CS-A

5q12.1

Required for TCR of transcribed strands

TTD-A

19q13.2-

Part of TFIIH complex

q13.3
PCNA

20pter-p12

Supports repair synthesis

RFC

3p27

Support DNA synthesis with Pol ε or δ

Latimer et al., 2002.

In eukaryotes, NER consists of four steps. It involves recognition, excision by
excinuclease, followed by DNA repair synthesis and ligation of the new DNA strand.
NER functions in two subpathways, global genomic repair (GGR) and transcription
coupled repair (TCR). They differ mainly in the initiation step because RNA polymerase
(Pol II) in TCR helps recruit the recognition complex to the damage site. The first step is
the rate limiting step and it involves the binding of XPA-RPA (Replication Protein A) to
the damaged DNA (Sancar, 1996). Recent reports indicate that this recognition step could
also be carried out by other complexes, namely XPC-hHR23B or XPE-XPC (Bernstein et
al., 2002). The complex recruits TFIIH to the lesion which in turn unwinds the double
strands of DNA. Both XPA and TFIIH help recruit XPC-hHR23 to the lesion. In
addition, both TFIIH and RPA recruit XPG to the damage site. XPG makes a 3/ incision
3-5 bases 3/ to the lesion. Simultaneously, XPA, XPF and TFIIH recruit XPF-ERCC1.
The latter complex makes a 5/ incision 20-24 nucleotides 5/ to the lesion. The
postincision complex is dissociated by RFC which also brings DNA synthesis machinery
including PCNA in association with Polymerase ε or δ. The gap is filled and DNA ligase
I makes two phosphodiester bonds linking the repair fragment (27-29 nt) to the backbone
of the DNA molecule (Sancar, 1996). Table I summarizes the different proteins involved
in NER and their function.
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Figure 1. General Scheme of NER.
NER is also linked to other
aspects of cell activities. First of all,
it was shown that NER functions
more efficiently on naked DNA than
on

nucleosome-associated

DNA

(refer to fig. 1). That might indicate
that NER machinery requires full
access to DNA with dissociation of
histones. Thus, in order for a cell to
repair UV-induced DNA damage,
factors (i.e. histone acetylation) other
than

the

approximately

30

polypeptides of NER, might be
required (Ura et al., 2002). Another
aspect is the relationship between
NER and apoptosis. The first link
comes from the fact that allelic
variations of XPD seem to decrease
the risk for lung cancer and that might

Hayes et al, 2002.

be due to increased apoptotic ability. Secondly, p33ING1b (enhances DNA repair after UV
exposure) was shown to induce apoptosis possibly through its ability to strongly bind to
PCNA in a UV-inducible manner. The strongest link, however, comes from the fact that
p53, a tumor suppressor gene, binds to the above mentioned members of NER and other
NER proteins like XPB. Through these interactions, p53 appears to inhibit the helicase
activity of TFIIH. Moreover, a study on mutant mice for p53 showed that UV treatment
induced NER and apoptosis in heterozygote mice but not in homozygotes. However, after
the UV exposure, apoptosis is not only dependent on p53 by itself; requires a
functional XPB and XPD. Finally, p53 is a transcriptional activator of XPE (Bernstein et
al. 2002).
7

5-Cytogenetics and Molecular Genetics of Breast Cancer:
Cancer is a multistep genetic disease, which shows a very complex pattern of
genetic mutations such as chromosomal aberrations. In the case of invasive breast cancers
(IBC), there is compelling evidence that they diverged from premalignant stages. For
instance, up to 80% of DCIS and LCIS share at least one to several LOHs with
synchronous IBC which indicates that they are genetically related (Harris et al., 2000).
Consequently, studying premalignant lesions should help elucidate the early steps of
carcinogenesis and metastasis. Interestingly, studies on DCIS have shown similar
mutations that involves tumor suppressor genes and oncogenes. For instance, 60-80% of
DCIS cases show loss of heterozygosity at 16p, 17q and 17p. Candidate genes on these
regions are E-cadherin on 16p, p53 on 17p, and NFI and BRCA1 on 17q. In addition,
LOH studies comparing DCIS lesions from non cancerous breasts to identical lesions
from cancerous breasts showed some patterns in
Table II. Proportional LOH.
Proportional LOH

the progression of IBC. For example, one study
showed an increase in LOH of marker D11S988

Arm

Normal CIS

Inv

from 20% to 70% in DCIS of non cancerous breasts

1p

0

0

0

compared to those of cancerous ones. This marker

1q

0.02

0.48

0.50

is close to the cell cycle-regulatory gene cyclin D1

3p

0

0.19

0

7q

0.01

0.07

0.06

11p

0.02

0.35

0.23

11q

0

0.32

0.41

16q

0.02

0.65

0.79

17p

0

0.38

0.64

17q

0.02

0.29

0.37

Xq

0

0

0

Bennett et al., 2002

on 11p (Harris et al., 2000). Another similar
comparison study on comedo DCIS (associated
with poor prognosis) showed an increase in LOH
from non cancerous to cancerous breasts for
markers D2S362 on 2q (10% to 40%), D13S137 on
13q (10% to 40%), and D17S597 on 17q 9 (5% to
40%). The majority of DCIS also showed gene
amplification of c-erb-b2 on 17q11.2-q12 (Harris et
al., 2000). In addition, Larson et al. (2002)
compared

LOH

and

allelic

imbalances

in

histologically normal ducts, terminal ductolobular units, carcinoma in situ (CIS) and IBC
(Inv) samples derived from 18 breast cancer patients. Table 2 summarizes their results
which reveal a pattern in chromosomal aberrations related to tumor progression.
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Moreover, Shen et al. (2000) screened 100 breast tumors for 400 microsatellite markers
using PCR and demonstrated that chromosomal instability is a major factor for
characteristic LOH. They attributed that observation to the loss of HRR because as
tumors evolve from well to moderately to poorly differentiated, they had found a
progressive pattern of LOH for markers linked to genes involved in HRR such as p53,
BRCA1, ATM, etc (Shen et al., 2000). Chromosomal loci linked to NER genes also
showed a high proportion of LOH. For instance, 9q22.33 was lost in 35% of welldifferentiated tumors. This is the location of XPA. Also, 17q13.3 (RPA 70 region) was
lost in 77.7% of poorly differentiated tumors. Despite the fact that the study was done on
tumors derived from non western women (Taiwanese), the results of LOH in 1q, 11p,
11q, 16q, 17p and 17q were consistent with those of western subjects. Finally, breast
tumors are characterized by their heterogeneity, but that might be a by-product of
divergent mechanisms inherent of tissues that show a great deal of genomic instability
(Harris et al., 2000).

6-SKY:
Since its development by Schrock et al. in 1996, spectral karyotyping (SKY) has
become more frequently used in medical diagnosis and for research purposes. The
technique became feasible after advancement and combination of optical spectroscopy
and charge-coupled device (CCD) cameras (Schrock et al., 2000). It is basically an
elaboration on FISH (Fluorescent in situ hybridization). Chromosome specific probes
with different fluorescent dyes (4-5) are used to hybridize simultaneously with the whole
chromosome set of the metaphases of interest. When the slide is examined under
fluorescent microscope, the fluorescent dyes are excited with light and will emit lights of
different wavelengths. Because of sequence specific hybridization, each chromosome
will hybridize with different sets of probes in different dyes proportions. As a result, each
chromosome will appear with a different color. The probes were obtained from
degenerate oligonucleotide-primed PCR performed on flow-sorted human chromosomes
with nucleotides conjugated with fluorescent dyes, such as Cy2, Cy3, Texas red and Cy 5
(Schrock et al., 1996). In addition, repetitive DNA sequences are blocked by an unlabeled
9

human DNA enriched with repetitive sequences, Cot-1 DNA, to minimize cross
hybridization (Schrock et al., 2000). Finally, a DAPI image is used with SKY as a DNA
counter stain for banding information. SKY is a powerful technique to reveal
chromosomal translocations and to identify translocation partners. Moreover, SKY is
especially helpful for cytogenetic analysis of tumor cells in identifying markers and
aberrant chromosomes. That is because tumor karyotypes usually have a poor banding
quality coupled with abnormal chromosomal count and multiple rearrangements which
makes it difficult to identify chromosomes.

However, SKY can only be used in

conjunction with conventional karyotype analysis because the latter is essential for
detection of intrachromosomal aberrations, such as small deletions, inversions and
duplications (Reid et al., 1997). The main clinical application of SKY is in diagnosis of
lymphomas. However, it has been increasingly applied to solid tumors like breast cancer.
For instance, one study tested 16 breast cancer cell lines for chromosome 8 abnormalities
(Rummukainen et al., 2001). The SKY test revealed extra chromosome(s) 8 in three cell
lines. Four other cell lines showed extra translocated chromosome(s). Many cell lines had
complex derivative chromosomes with chromosome 8 material. The main translocation
partner for 8 was found to be chromosome 11. Interestingly, the c-myc oncogene resides
on 8q24. In another study, immortalized human mammary epithelial cells MCF10A were
treated with the mutagen benzo[a]pyrene (Caruso et al., 2001). The cells were tested for
loss of contact inhibition and anchorage- dependent growth as indicators of
transformation. Cytogenetic analysis of both transformed and regular MCF10A cells
using conventional karyotyping and SKY revealed an isochromosome 8 in the
transformed cells, while both cell types shared a der(3) and a der(9).

This study is interested in early events in carcinogenesis of breast cancer with a
special focus at loss of NER and genetic instability. Several early stage cancer and
normal tissue cultures derived from breast cancer patients were karyotyped. In addition,
MCF10A cells were cytogenetically studied as a model for early steps in carcinogenesis.
To further elucidate the chromosomal abnormalities present, SKY analysis and multi
probe FISH for breast cancer aneusomy were performed on a DCIS case and MCF10A
cells.
10

II. Materials & Methods
1-Regular Karyotype:
Established cell cultures were fed every other day with 5 ml of Alpha MWRI media
in 25 cm2 flask and incubated at 370 C. Once confluent, cells were seeded into large petri
dishes. Cell growth was monitored. When enough mitoses (rounded up cells) were
observed, usually after 1-2 days, 20-45 µl of colcemid (stock concentration of 10 µg/ml)
was added and the culture was left in the incubator overnight ( the amount and the length
of time of colcemid addition varied depending on the mitotic index of the culture).The
culture was then visualized under the microscope for mitotic cells. If enough mitotic cells
were found, the culture was harvested.

First, the media was collected with a plastic pipette in a 10 ml conical tube. Then, the
flask was washed with 5 ml Hank’s solution (HBSS: phosphate saline buffer solution
without Ca++ and Mg++). The solution was added to the conical tube and the cells were
harvested with 1 ml trypsin for 5 min in the incubator. Cells were washed from the flask
with the solution in the conical tube. The solution, with the unattached cells, was
transferred back to the tube. The cells were centrifuged at 1300 RPM for 8 min. The
supernatant was decanted, and the cells were resuspended in 1 ml of 0.1% sodium citrate
hypotonic solution. An additional 9 ml of the hypotonic solution was added and mixed.
The cells were incubated in a water bath for 10 min at 370 C. The tube was centrifuged at
1300 RPM for 8 min, and the supernatant was decanted. The pellet was resuspended in 1
ml fixative solution (3 methanol: 1 acetic acid). An additional 4 ml of fixative was added,
and the cells were refrigerated for 1 hr. After that, the cells were centrifuged at 1300
RPM for 8 min. The supernatant was decanted and the cells were resuspended in 5 ml of
fixative. The previous step was repeated 3 times reducing the volume of fixative by 1 ml
each time. After the final centrifugation, the supernatant was decanted and the cells were
resuspended in about 1.5 ml of fixative, depending on the size of the pellet. The cells
were then dropped using a 5.75 inch paster pipette on a preheated super frosted
microscope slide held at a 450 angle from a distance of about 10 inches (the slides were
11

preheated in a 650 C water bath). The slides were air dried and incubated at 600 C for
overnight.
For conventional karyotype, cells were banded by dipping slides in trypsin in a coplin
jar for 25-30 S. The slides were washed briefly in two saline rinsing solutions. Then, they
were stained with 5% Giemsa in a coplin jar for 6.5 min. The slides were rinsed with tap
water and air dried. Finally, the slides were examined under the microscope for
metaphases. A minimum of 10 metaphases were randomly chosen and used to determine
the karyotype of the tissue culture.

2-MCF10A Cell Cultures and Harvest:
MCF10A cells were grown in 25 cm2 flasks in 5ml MGEM media (Clonetics).
The media consisted of 500ml of the Bullet Kit bottle, 0.5ml of 10µg/ml hEGF (human
recombinant Epithelial Growth Factor), 0.5ml of 5mg/ml Insulin, 0.5ml of 0.5mg/ml
Hydrocortisone, 0.5ml of 50mg/ml Gentamycin-50µg/ml Amphotericin, and 2ml of
13mg/ml Bovine Pituitary extract. Prior to use, 20µl of cholera toxin was added to 100ml
of medium. Cells were fed with the addition of 1ml of medium every other day. The
culture was sub-cultured once every week by the following procedure. The supernatant
was aspirated, washed with 3ml HBSS, and aspirated again. The culture was treated with
0.5ml HBSS and 2ml of trypsin solution consisting of 10ml of 1X trypsin (0.25% trypsin
and 0.02% EDTA), 0.4ml of 2% EDTA in HBSS, and 39.6ml of HBSS. The treatment
lasted for 15-20 min in the incubator with slight shaking of the flask every 5 min. After
cells were ready, 0.5ml Fetal Bovine Serum (FBS) was added, cells were pipeted and
collected into a 10ml conical tube. The tube was centrifuged for 5 min at 800 rpm. The
supernatant was discarded and cells were resuspended in 4ml of medium. Finally, cells
were sub-cultured into flasks by the ratio 1ml suspension solution: 3ml culture media.
The same trypsin treatment was used for harvesting cultures. Once harvested, cells were
treated with hypotonic solution, fixative solution, and slide dropping with the same
procedure of other cultures mentioned in the regular karyotype section. After dropping,
slides were either G-banded, used for SKY or for FISH.
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3-Spectral Karyotyping (SKY):
The protocol of the manufacturer (Applied Spectral Imaging) was followed with
little modifications. On day one, the probe was denatured. Ten µl of the probe mixture
(vial #1) was centrifuged briefly, incubated in water bath at 800 C for 7 min, and placed in
a water bath at 370 C for 1 h. In the mean time, the slides were treated with pepsin
solution preheated at 370 C for 2 min. Then they were washed twice in 1X PBS for 5 min
each at room temperature and with 1X PBS/MgCl2 for 5 min. The slides were then
incubated in 1% formaldehyde for 10 min at room temperature and washed again with 1X
PBS for 5 min. The slides were dehydrated in 70%, 80% and 90% ethanol for 2 min each.
The chromosomes were denatured by dipping slides in 40 ml of preheated denature
solution for 60-90 s at 700 C. The slides were again dehydrated in 70%, 80% and 90%
ethanol for 2 min each and were allowed to air dry. By that time, the probe from vial#1
was already denatured. The 10 µl probe was transferred to the slide. An 18x18 mm2 cover
slip was placed on the hybridization area leaving no air bubbles. It was sealed with rubber
cement. Finally, the slide was transferred to a humidified chamber and placed in an
incubator at 370 C for 36 hrs.

On day three, the rubber cement and the cover slip were gently taken off. The
slides were washed 3 times with washing solution I at 450 C for 5 min each. They were
then washed twice in washing solution II at 450 C for 5 min and once in washing solution
III for 2 min at 450 C. They were then briefly tilted to drain the fluid and 80 µl of vial#3
was applied. The slides were covered with cover slips (24x60 mm2) and incubated at 370
C for 45 min. They were washed again 3 times with washing solution III at 450 C for 3
min each. The hybridization area was treated with 80 µl of vial#4, covered with a plastic
cover slip and incubated at 370 C for 45 min. Again, washing steps with washing solution
III were repeated. After that, the slides were washed with water and then air dried. The
slides were then stained with 20 µl of DAPI/antifade and covered with cover slips
avoiding any air bubbles. The slides were then examined under a fluorescent microscope.
Images were taken and analyzed with the Skyvision Spectral Imaging System. Both the
sky color and the DAPI were used to assign chromosomes and to determine the origin of
translocated chromosomes.
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Reagents for SKY (Applied Spectral Imaging):
-

0.01M HCl: 0.5 ml 1M HCl added to 49.5 ml of distilled water.

-

1x PBS/MgCl2: add 50 ml of 1M MgCl2 to 950 ml of 1X PBS.

-

1% formaldehyde: add 2.7 ml of 37% formaldehyde to 100 ml of 1X PBS/ MgCl2.

-

Denaturation solution: add 35 ml formamide to 10 ml distilled water and 5 ml
20X SSC.

-

Washing solution I: 15 ml 20X SSC, 60 ml of distilled water and 75 ml
formamide. Adjust pH to 7.0 with HCl.

-

Washing solution II: mix 12.5 ml 20x SSC with 237.5 ml of distilled water.

-

Washing solution III: 400 ml of distilled water, 100 ml of 20X SSC and 0.5 ml of
Tween 20.

-

Vial#1: Probe mixture

-

Vial#3: buffer one. Prior to use, 10 µl of the buffer were diluted in 1 ml of 4X
SSC.

-

Vial#4: Buffer two. Prior to use, 5 µl of the buffer were added to 1 ml of 4X SSC.

4-Aneusomy Multi-Probe FISH:
The manufacturer’s protocol was used with few modifications (Vysis). Slides
were treated in 2X SSC for 2 min at 700 C. Then, slides were digested for 10 min at 370 C
in a protease solution prepared from 0.02g of pepsin, 40ml of H2O and 0.4ml of 1N HCl.
Slides were rinsed in PBS at room temperature for 5 min and placed in post fixative
solution for another 5 min at room temperature. The post fixative solution consisted of
1ml of 37% formaldehyde, 0.18g of MgCl2, and 39ml of PBS (stored at 40 C for a
maximum of 1 month). Slides were rinsed in PBS for 5 min at room temperature. Finally,
slides were dehydrated in ethanol series (70%, 80%, and 90%) for 2 min each. Slides
were air dried and were ready for hybridization.

For hybridization, the probe mixture was warmed at room temperature (all work
with the probe was performed in the dark). The tube was vortexed and microcentrifuged.
10µl of probe mixture (3µl of probe and 7µl of tissue DenHyb) were applied to selected
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area of the slide. Slides were covered with 22X22 coverslip and sealed with rubber
cement. The HYBrite system was used for denaturation and hybridization steps. It was
set at 730 C for 2 min and at 390 C for 16 hours. After that, rubber cement and coverslips
were removed. Slides were washed at 730 C for 2 min in 0.4X SSC/0.3% NP-40 (40 ml
0.4X SSC and 0.12ml NP-40). They were rinsed in 2X SSC/0.1% NP-40 (40ml 2X SSC
and 0.04 ml NP-40) for 1 min at room temperature. Slides were air dried, stained with
20µl of DAPI counterstain and covered with coverslips for scoring. One hundred cells
were scored for each case with gold for cosmid1p12 probe, red for 8 centromeric probe,
green for 11 centromeric probe and aqua for 17 centromeric probe.

5-C-MYC-IGH FISH Probe (Vysis):
The same pretreatment as the above was applied. For hybridization, 10µl of probe
mixture (1µl of probe and 49µl of DenHyb) was applied to the slide. Slides were sealed
with cover slips and rubber cement and hybridized. Using the HYBrite, program was set
at 900 C for 4 min and at 370 C for 16 hours. After that, the coverslip and the rubber
cement were removed. Slides were washed, air dried, DAPI-counterstained and scored
(the same as aneusomy probe procedure). The probe for c-myc on chromosome 8q24
appeared in red, the probe for IGH on chromosome 14q32 appeared in green and the
probe for chromosome 8 appeared in aqua.
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III. Results
Established cell lines from The University of Pittsburgh and one cell line
(courtesy of Dr. J. Strobl) were karyotyped. For two of the cultures, DCIS NTAL3 and
MCF10A, SKY and FISH probes for both Breast Aneusomy (courtesy of Vysis) and
IGH/c-myc (Vysis) were used for their characterization.
Table III. General Characteristics of the Cultures Studied.
Culture

Type of Tissue

BRL11
BRL14
BRL16

Breast Reduction
Breast Reduction
Breast Reduction

DCIS
NTAL3
BTL12

Ductal carcinoma in 39
situ
Ductal
carcinoma 37
stage 3A
Fibrocystic disease, mammary gland and
breast tissue.

MCF10A

Age of
Patient
19
25
56

Pathology

Karyotype

Benign
Fibrocystic Changes
Ductal
epithelial
hyperplasia
and
fibrocystic changes
Stage 0 cancer

Normal, 46,XX
Normal, 46,XX
Abnormal

Stage 3A

Abnormal

Abnormal

Immortalized
human Abnormal
epithelial cells (breast
cell Line)

16

1- MCF10A:
Figure 2. MCF10A karyotype.

Based on conventional karyotyping, the composite karyotype was: 45-48,XX,i(1)(q10),3,del(3)(p13),+4,der(8),+der(9), der(9),+19.
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SKY:
Figure 3. Spectral Karyotyping of MCF10A Cells.

The image shows the derivative chromosomes 8, 9, i(1)(q10), del(3)(p13).

Table IV.Percentages of abnormalities in MCF10A.*
Der(9) +19 +4
Abnormality i(1)(q10) der(8) +der(9) del(3)(p13) -3
100%
80%
60%
40%
30% 30%
30% 20%
percentage
*10 cells were analyzed based on the results of conventional karyotypes and SKY.

IGH/c-myc FISH Probe:
Figure 4.Duplication of C-myc in MCF10A Cells by FISH.

All cells had a normal signal for chromosome 14 (green). However, for c-myc, 18% had two red signals
(normal), 72% had 3 signals, and 10% had 4 for signals.
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Aneusomy FISH Probe:
Figure 5. Aneusomy Fish Probe of MCF10A Cells.

83% of the 100 cells had a normal signal (2 of each) for all probes. A total of 17 cells (17%) had one or
more abnormal signals.

Table V. Percentages of MCF10A Cells showing irregular Aneusomy FISH Probe
Signal.
Signal Irregularity
1 extra red
1 missing red
1 extra green
1 extra aqua
2 extra aqua
1 missing aqua
1 extra gold
2 extra gold
1 missing gold

Percentage
3%
2%
(11)
3%
(17)
4%
2%
3%
(1p12) 4%
2%
2%
(8)
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2-BRL16 (Ductal epithelial hyperplasia and fibrocystic changes).
Figure 6. BRL16 Karyotype.

The composite karyotype of BRL16 was: 44-49,+del(6)(q21)*.
*The del(6)(q21) appeared in 4 out of 11 cells.

3-DCIS NTAL3
Composite Karyotype: 59-110,XX,X,+1,+1,add(1)(p22),+2,+2,+3,+del(3)(p21),+del(3)
(q21),+4,+5,+5,+dup(5)(q13q22),+6,+del(6)(q13),+del(6)(q13),+del(6)(q21),+7,+7,+7,+8
,+9,+del(9)(p22),+del(9)(p22),+10,+10,+11,+11,+11,+12,+13,+13,+13,-14,+15,
add(15)(p11.2),+16,+16,+17,+17,+17,+del(17)(p13),+del(17)(p13),+18,+18,+19,+19,+19
,+19,+20,+20,+21,+21,+22,+22,+2-19mar[cp10].
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Figure 7. DCIS NTAL3 Regular Karyotype.

Table VI. Percentages of at Least One1 Additional Chromosome in DCIS Cells.
Chromosome
Percentage2
Chromosome
Percentage
Chromosome
Percentage

+4
95%
+13
77%
+15
32%

+17
95%
+22
73%
+18
27%

+20
95%
+8
68%
+X
27%

+7
91%
+12
68%

+9
91%
+16
68%

1

+19
91%
+21
68%

+1
86%
+5
59%

+11
86%
+3
41%

+2
81%
+6
41%

+10
77%
+14
41%

Only one additional chromosome was counted per cell. Some cells had more than one addition for a
particular chromosome. These were counted as one incidence.
2
Percentages were calculated per 22 conventional karyotypes.
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Table VII. Percentages (per 22 cells) of Aberrant Chromosomes in DCIS
Karyotypes.
Chromosomal
Aberration
+del(9)(p22)
+del(3)(p21)
+del(17)(p13)
+del(3)(q21)
+del(6)(q21)
+del(6)(q23)

Percentage
68%
64%
59%
45%
27%
22%

SKY:
Figure 8. SKY Analysis of DCIS Metaphases.

22

Table VIII. Chromosomal Aberrations Percentages in DCIS as Revealed by SKY
(4cells).
Chromosomal aberration

Percentage

der(2)t(2;15)(q10;q10)
der(6)t(6;14)(q13;q11.2)
der(1)t(1;19;10)(p13;?;q22)
der(15)t(15;22)(p11.2;q11.2)
der(4)t(4;20)(q31.1;q11.2)
der(2)t(4;2;4)(q21;p11.2q31;p14)
der(14)t(14;21)(p11.2;q22)
der(2)t(1;2)(p32;p13)
der(8)t(2;8)(q33;p11.2)
der(1)t(1;6)(q21;q21)
der(1)t(1;14)(p22;q11.2)

100%
100%
75%
75%
75%
50%
50%
50%
50%
25%
25%

IGH/c-myc FISH Probe:
Figure 9. C-myc in DCIS Cells by FISH.
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Table IX. IGH/c-myc FISH Probe for DCIS Cells.
Percentages of Cells___________
Extra Signals

Green (14)

Red (c-myc)

Aqua (8)

-1

-

-

1

0

1

3

10

1

8

20

83

2

42

52

5

3 or more

49

25

1

Table X. Percentages of DCIS Cells with C-myc/Chr.8 Ratios as Revealed by FISH.
Ratio*
Percentage

<1
2%

1(normal)
21%

1.33
41%

1.50
3%

1.67
16%

1.67<X<4
17%

*Ratios were calculated as the # of red signals (c-myc) relative to the # of aqua signals (chr. 8) for each
cell. Cells, with ratios larger than 1, had gained c-myc copies relative to chromosome 8 and visa versa.

Aneusomy FISH Probe:
Figure 10. Aneusomy FISH Probe of DCIS Cells.

None of DCIS cells had a normal set of aneusomy probes signal.
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Table XI. Percentages (per 100) of DCIS Cells with Different Aneusomy Probe
Signals.
Abnormal signals
One extra red (chr.8)
Two extra red
Normal red
At least two extra green (chr.11)
Two extra green
Three or more extra green
Normal green
Missing one aqua (chr.17)
One extra aqua
Two or more extra aqua
Normal aqua
One extra gold (chr.1)
Two extra gold
Three or more extra gold
Normal gold

Percentage of Cells
87%
10%
3%
100%
35%
65%
0
8%
21%
61%
10%
10%
38%
50%
2%

4-BTL12 (Ductal carcinoma stage 3A).
Figure 11. BTL12 Karyotype.
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The composite karyotype of BTL12 was: 70-72,XX,+X,+del(1)(q41),+der(1)t(1;2)(p32,q11.2), i(2)(p10),3,+del(3)(q21),+4,+4,+5,+6,+add(6)(q25),+add(7)(q36),+8,+8,+9,+10,+add(11)(p15),
t(11;15)(p11.2;q11.2),del(12)(p11.2),add(13)(q34),+14,+15,+16,+16,+17,+19,+add(19)(q13.3),+20,+20,
+21, der(22)t(2;22)(q13;q13),+1-4mar [cp7].

Table XII. Percentages of Additional or Lost Whole Chromosomes in BTL12 Cells.
Chromo- +6
some
83
%*

+5

+9

+10 +14 +21 +4

+8

+17 +20 +16 ++14 -3

75

75

75

58

58

67

67

58

58

*Percentages were calculated per 12 cells.

Table XIII. Percentages of Abnormal Chromosomes in BTL12.
Abnormal Chromosomes
add(11)(p15)
der(1)t(1;2)(p32;q11.2)
der(11)t(11;15)(p11.2,q11.2)
del(3)(p21)
del(17)(p13)
+add(6)(q25)
add(7)(q36)
add(13)(q34)
der(22)t(2;22)
i(2)(p10)

Percentages*
75%
67%
58%
58%
58%
42%
42%
42%
33%
25%

*Percentages were based on analysis of 12 cells
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50

33
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IV. Discussion
Cytogenetics is an indispensable tool for the study of cancer. It is an important
step for research purposes for the identification of frequent chromosomal aberrations.
Once identified, the aberrations can be used for research purposes as a step in the
identification of gene(s) involved (i.e. oncogenes or tumor suppressor genes) in
carcinogenesis. In addition such findings might be essential for diagnostic and prognostic
purposes. Of special interest for this study was breast cancer. Previous research using
cytogenetic techniques has shown the involvement of certain abnormalities in breast
cancer. In this study, different tissues were analyzed to try to establish the role of NER
loss and genetic instability at different levels and to compare the chromosomal
aberrations in these levels.

1-MCF10A:
Caruso et al. have shown a der(8) and der(3) in these immortalized non tumor
cells. In this study, der(8) was found using SKY (figure 3) and conventional karyotyping
(figure 2). The chromosome did not seem to have other chromosomal materials than 8 in
SKY. An amplification of c-myc was suspected. Indeed, FISH (figure 4) showed an extra
c-myc signal in 82% of interphase cells compared to 80% incidence of the der(8) in
metaphases karyotypes. Consistent with the previous results from karyotyping and SKY,
the cells also had a normal signal for both chromosomes 14q32 and 8 centromere.
Whether c-myc duplication contributes to the immortal characteristic of MCF10A cannot
be based on this study. However, it is important to note that the protein is highly
expressed in MCF10A cells (Melkoumian et al., 2002). In fact, MCF10A cells showed
higher expression of myc protein than the tumorigenic cell line MCF-7. In addition,
based on SKY results, a suspected chromosome 8 was shown to be a del(3)(p13). It also
showed that a previously classified extra chromosome 2 was in fact a der(9). However, an
i(1)(q10) was found in 100% of cells. Such chromosome does not only entail the
existence of an additional 1q arm but also that one 1p is missing. The loss of 1p was
shown to be progressive and recurrent in breast cancer (Larson et al., 2002). Whether this
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aberration is an initial event or acquired later, remains to be determined. However, the
fact that it was found in a 100% of cells implies that it is an early event. Otherwise, it will
appear in some cells but not all. Besides, the cell line seemed to be stable and non
cancerous (both passage 14 and 15 had similar karyotypes). Finally, MCF10A had a
generally normal signal for the aneusomy FISH probe (figure 5 & Table V) which
indicate a normal 1p12, 8, 11, 17. The 1p12 FISH does not necessarily contradict the
i(1)(q10) because the 1p12 is very close to the centromere and the breakpoint could have
happened beyond the probe point.

2-BRL16:
BRL16 had an abnormal karyotype (figure 6) but relatively stable by their small
range of their chromosomal count and the few abnormal events. Chromosomal
abnormalities varied between cells. The only consistent event was an extra del(6)(q21) in
4/11 cells (36%). However, in this case, there is an extra 6p rather than a lost 6q.
Nevertheless, 6q is selected against in that cell culture otherwise an additional whole
chromosome 6 will be a more likely event. This karyotype could be considered as a link
between hyperplasia and 6p.

3-DCIS NTAL3:
Conventional karyotyping of DCIS cells revealed a very aberrant karyotype
(figure 7). The multiple events including translocations, deletions and duplications made
these cells almost impossible to karyotype. This is reflected in the large number of
markers that were left unclassified. In order to further analyze chromosomal
abnormalities, SKY was used for this cell culture. SKY proved to be very helpful to
classify unknown markers, reveal a great deal of translocations and their partners and
solidify the classification of known chromosomes. SKY also helped reclassify mistakenly
classified chromosomes like chromosomes 17, 6p, 3, etc.

Table VI shows percentages of additional chromosomes in DCIS. All
chromosomes appeared to have occurred additionally. However, if these cells were
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looked at as polyploidy, the results could have been completely different. Since these
cells did not follow any clear pattern of polyploidy in their chromosomal count and
classification, it made it difficult to assign a certain level of polyploidy for these cells.
Nevertheless, a careful look at these karyotypes suggests that additional chromosomes
that occurred with lower percentages also had fewer copies and were more likely to be
lost in other cells. For instance, chromosome X, which was found in additional number in
27% of cells, had an average copy number of 2.14 per cell; meanwhile one copy was lost
in 23% of cells. On the other hand, chromosome 4, which was found in additional
number in 95% of cells, had an average copy number of 3.36 per cell, meanwhile one
copy was lost only in one cell (less than 5%). Besides, all cells had above normal
chromosomal counts (59-110 chromosomes). All these factors suggest that numbers in
table VI should not be taken as absolute. In fact, since there are chromosomes with high
proportion of additional occurrence while there are others with a low incidence suggests
that there is a selection pressure for the acquisition of certain chromosome and the
relative loss of others. Independent from selection, all these chromosomes should have a
similar proportion of additional occurrence. Finally, it is difficult to attribute these
additions to certain genes for two reasons. First of all, chromosomes contain a large
number of genes that might contribute positively or negatively to the survival of these
cells. That selection is a reflection of the balance of pros and cons. For instance,
chromosome 17 contains the genes for p53 and BRCA1; yet, DCIS cells show a high
percentage of additional chromosome 17(s). One can draw the conclusion that there are
other genes on chromosome 17 that increases the survival of DCIS. That also helps
explain the selection of certain deletions in cancer as discussed later. Secondly, the
incidence of additional chromosome doesn’t ensure that all genes on that chromosome
are expressed normally. Other factors like epigenetic changes, regulatory elements, etc.
are equally important.

The selective pressure of carcinogenesis is manifested more clearly in
chromosomal aberrations (table VII) because these events are normally less common and
more complicated. Thus their recurrence is more relevant to the survival of these cells
than to mere chance. The recurrent aberrations included deletions 9p, 17p, 3p, and 6q.
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These findings are consistent with previous research (Larson et al., 2002). The 17p
contains p53 and 3p contains three NER genes including XPC, RFC and TFIIEp56. It
also contains the tumor suppressor gene fragile histidine triad (FHIT) which shows
frequent LOH in breast cancer. On the other hand 6q26-6q27 contains the tumor
suppressor gene ST8 (suppressor of tumorigenicity 8). This gene was shown to be
involved in familial ovarian cancer. However, breast cancer was shown to aggregate in
affected families (OMIM).

SKY analysis (table VIII & figure 9) has revealed multiple translocations. Some
of these aberrations occurred more than once within the same cell, such as
der(6)t(6;14)(q13;q11.2). The impact of these translocations cannot be elucidated in this
study. However, they are reminiscent of those in leukemias that allow the constitutional
expression of an oncogene or a dominant negative protein. Molecular analysis of these
translocations might be of great help in identifying these genes. All in all, SKY revealed
a great deal of genomic instability manifested by multiple translocations, derivative
chromosomes with multiple chromosomal partners and the abundance of small fragments
of different chromosomes.

The c-myc FISH probe revealed multiple copies of chromosomes 8, 14 and of cmyc gene (Table IX). The number of extra chromosomal copies especially for
chromosome 14 exceeds that of karyotyping (99% compared to 41%) and that could be
due to its participating in different translocations in addition to the small fragments of
chromosomal material (which also affected the aneusomy probe). Moreover, a
comparison of the number of chromosome 8 copies and c-myc reveals an excess of c-myc
in 77% of the cells (Table X). This is an indication of c-myc amplification in these cells.
In the aneusomy probe (Table XI), at least one extra red was found in about 90% of cells
(similar to the centromere 8 of IGH/c-myc probe). However, this is higher than the
proportion of cells with an extra chromosome 8 derived from karyotypes (68%) for the
aforementioned reasons. Likewise for chromosome 11 and the green signal in which
additional copies were seen in 100% of the cells. The aqua probe for chromosome 17 was
the only one to show a loss of one signal in 8% of the cells in contradiction to the
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karyotypes that reveal additional copies of chromosome 17. This might be due to errors
in reading the FISH results since aqua had a small signal. Nevertheless, more than 80%
of cells showed extra signal(s) for aqua. Chromosome 1 had a very high proportion of
extra signals (a total of 98%) that exceeds the proportion derived from karyotypes (86%).
That is because chromosome 1 was a partner in many translocations and could have been
classified in the position of other chromosomes based on the centromere while the probe
detects the p arm regardless the origin of the centromere.

4-BTL12:
BTL12 had an abnormal karyotype (figure 11). Cells seemed less heterogenous
and more stable than DCIS. That might reflect a monoclonal origin of cells or the high
selective pressure that allow cells with very strict prerequisites to reach that phase of
cancer (Stage 3A). Only 9 chromosomes were present in extra copies and in different
proportions (Table XII). Noticeably was the loss of chromosome 3 in 17% of the cells.
The cells also showed multiple translocations (Table XIII). These aberrations will be
discussed more thoroughly in the next section.

5-General comparison:
First of all, one of the earliest steps in carcinogenesis is continuous proliferation
of cells. In that sense, both MCF10A and BRL16 could be used as models for early
events in the evolution of cancer. Of special interest in MCF10A alterations was the 3p
deletion, c-myc duplication and i(1)(q10). 3p deletion is consistent in DCIS (64%) and
BTL12 (58%) cells. Besides, chromosome 3 was lost in 17 % of BTL12 cells. Added
together, the p arm was lost in 75% of BTL12 cells. Considering the type of genes on 3p,
that deletion could help explain the loss of NER in DCIS cells. Based on the consistency
and early nature of 3p deletion, that event might be essential for the development and
progression of breast cancer. The second event is the duplication of c-myc in both
MCF10A and DCIS. C-myc was not studied in the other cell cultures but is known to be
amplified in breast cancer. As an oncogene, it is a reasonable candidate for the immortal
characteristic of MCF10A and the proliferation of DCIS. It might also have a role in the
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malignancy of BTL12 since chromosome 8 occurred additionally in 58% of the cells.
The third event is the aberration of chromosome 1. Isochromosome 1q was found in
100% of MCF10A cells. In addition, all DCIS had at least one translocation involving
chromosome 1 especially 1p (table VIII). Translocation partners included chromosomes
2, 6, 10, 14 and 19. Moreover, der(1)t(1;2)(p32;q11.2) was found in 67% of BTL12 cells.
These results are consistent with previous research that found frequent aberrations in
chromosome 1 in primary breast tumors (Shen et al., 2000). The gene for NER regulatory
subunit, RPA70; is on 1p35. The p arm also contains numerous oncogenes involved in a
variety of tumors like c-Jun, RAS, and FGR. These translocations might provide a
mechanism for constitutional expression of such genes with the subsequent escape from
cell cycle regulations.

On the other hand, BRL16 had a rather different aberration, i.e. a del(6)(q21) in
36% of cells. The same deletion was found in DCIS (64%) and BTL12 (58%). Clearly,
the deletion occurs in a significant percentage of cells and shows an abrupt increase from
BRL16 to DCIS. It is also maintained in BTL12 cells. The fact that it did not keep
increasing in BTL12 (from DCIS to metastasized ductal carcinoma) might be due to
changes in the selective pressure. As cancers evolve different mutations are required. For
instance, cells need different mutations to escape cell cycle regulation. However, in order
for cancer cells to metastasize, they need other mutations like the expression of growth
factors and their receptors. This also helps explain the differences in chromosomal
additions between DCIS and BTL12 cells like in the cases of chromosomes 4, 6, 14, 17,
20, etc (table XIV). Both +6, and +14 increased in frequency. However, for the most part,
chromosomes were lost especially for chromosome 3 where it moved from being
additional to the subsequent loss of one normal 3. This demonstrated the dynamic nature
of cancer where certain genetic combinations are required at a certain stage while other
combinations are required for the other stage. Based on these results one can hypothesize
that genomic instability in DCIS cells allow the cells to acquire a great deal of
chromosomal aberrations expressed by the almost arbitrary gains of chromosomes.
However, once the cells were able to acquire these initial mutations, then they are
subjected to a great deal of selective pressure that will only allow certain cells with the
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Table XIV. Comparison of Chromosomal Additions between DCIS and BTL12
Chromosomal
addition
+14
+6
+5
+9
+21
+10
+8
+16
+4
+17
+20
32

Percentages in DCIS Percentages in BTL12

Difference1

41%
41%
59%
91%
68%
77%
68%
68%
95%
95%
95%
+3: 41%

+58%
+42%
+16%
-16% (loss)
-1%
-2%
-10%
-18%
-37%
-37%
-37%
-58%

99 (0.67+0.33) %
83%
75%
75%
67%
75%
58%
50%
58%
58%
58%
-3: 17%

1

The difference was calculated as the frequency of the incidence in BTL12 minus DCIS. A positive
difference sign indicates a progressive increase in that addition. A negative sign indicates a progressive loss
2
of that addition. Chromosome 3 was additional in DCIS and lost in BTL12.

appropriate genetic makeup to survive. Indeed, BTL12 (although a more advanced cancer
stage) showed fewer chromosomal abnormalities, a narrower chromosomal count range
and fewer random events than DCIS. This might suggest that as cells progress through
malignancy, the chances for randomness of events decreases because of the higher
burden of selective pressure. As a result, one might expect genomic instability to be high
in early stages of cancer but that might not hold true for later stages.

Finally, yet another aberration, del(17)p(13), occurred in 59% and 58% of cells in
DCIS and BTL12, respectively. The fact that it occurred in DCIS indicates that it is an
early event. Since p53 is on that arm, that loss might have a role in the genomic
instability in DCIS cells because p53 is very important for cell cycle regulation, apoptosis
and DNA repair.
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V. Conclusion
This study has shown some events in the carcinogenesis of breast cancer such as;
17p deletion, chromosome 1 aberrations, c-myc duplication, 3p deletion and 6q deletion.
These events were also found in non malignant immortal cells (MCF10A) or in ductal
epithelial hyperplasia (BRL16) illustrating for their role as early events. In addition,
DCIS cells were shown to manifest a great deal of chromosomal aberrations and genomic
instability. That was explained in part by one major event, 3p deletion, because 3p
contained three NER genes. The genomic instability could also be explained by 17p
deletion because it has the p53 gene. Moreover, genomic instability, in itself, seems to be
the mechanism through which cells can achieve malignant transformation. Finally,
further research is needed to demonstrate loss of NER in early tumors. Besides,
expression studies on suspected regions are needed to show whether genes expression in
these regions is altered in malignant transformation. One such region is 1p since it
contains numerous oncogenes and participated in many translocations.
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